International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(20), P. 11091 - 11091
Published: Oct. 15, 2024
Immune
checkpoint
inhibitors
(ICIs),
such
as
durvalumab,
tremelimumab,
and
atezolizumab,
have
emerged
a
significant
therapeutic
option
for
the
treatment
of
hepatocellular
carcinoma
(HCC).
In
fact,
efficacy
ICIs
single
agents
or
part
combination
therapies
has
been
demonstrated
in
practice-changing
phase
III
clinical
trials.
However,
confront
several
difficulties,
including
lack
predictive
biomarkers,
primary
secondary
drug
resistance,
treatment-related
side
effects.
Herein,
we
provide
an
overview
current
issues
future
challenges
this
setting.
Clinical and Molecular Hepatology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 26, 2024
Hepatocellular
carcinoma
(HCC)
is
a
major
global
burden,
ranking
as
the
third
leading
cause
of
cancer-related
mortality.HCC
due
to
chronic
hepatitis
B
virus
(HBV)
or
C
(HCV)
infection
has
decreased
universal
vaccination
for
HBV
and
effective
antiviral
therapy
both
HCV,
but
HCC
related
metabolic
dysfunction
associated
steatotic
liver
disease
(MASLD)
alcohol-associated
(ALD)
increasing.Biannual
ultrasonography
serum
α-fetoprotein
are
primary
surveillance
tools
early
detection
among
high-risk
patients
(e.g.,
cirrhosis,
HBV).Alternative
such
blood-based
biomarker
panels
abbreviated
MRIs
being
investigated.Multiphasic
CT
MRI
standard
diagnosis,
histological
confirmation
should
be
considered,
especially
when
inconclusive
findings
seen
on
cross-sectional
imaging.Staging
treatment
decisions
complex
made
in
multidisciplinary
settings,
incorporating
multiple
factors
including
tumor
degree
dysfunction,
patient
performance
status,
available
expertise,
preferences.Early-stage
best
treated
with
curative
options
resection,
ablation,
transplantation.For
intermediatestage
disease,
locoregional
therapies
primarily
recommended
although
systemic
may
preferred
large
intrahepatic
burden.In
advanced-stage
immune
checkpoint
inhibitor
(ICI)-based
regimen.In
this
review
article,
we
discuss
recent
epidemiology,
risk
factors,
care
continuum
encompassing
surveillance,
staging,
treatments.
Clinical and Molecular Hepatology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 6, 2025
Background/Aims:There
are
no
hepatocellular
carcinoma
(HCC)
surveillance
recommendations
for
non-viral
chronic
liver
diseases
(CLD),
such
as
metabolic
dysfunction
associated
steatotic
disease
(MASLD).We
explored
the
Steatosis-Associated
Fibrosis
Estimator
(SAFE)
score
to
predict
HCC
in
MASLD
and
other
CLD
etiologies.
Methods:Patients
with
various
CLDs
were
included
from
medical
centers
Taiwan.The
SAFE
score,
consisting
of
age,
BMI,
diabetes,
laboratory
data,
was
calculated
at
baseline,
patients
traced
new
development
HCC.The
predictability
analyzed
using
subdistribution
hazard
model
adjustments
competing
risks.
Results:Among
12,963
a
median
follow-up
4
years,
258
developed
classifies
1,
3,
5-year
risk
regardless
etiologies.High
(≥100)
intermediate
(0-100)
scores
increased
11
2
folds
risks
compared
low
(<0)
scores.Combining
two
lower
tiers
(SAFE
<
100),
high
7.5-fold
(adjusted
sub-distributional
ratio
[aSHR]:
7.54,
95%
confidence
interval
(CI):
5.38-10.60).A
subgroups
viral
hepatitis,
hepatitis
(aSHR:
11.10,
95%CI:
3.97-31.30)and
4.23,
1.43-12.50).A
hospital
cohort
(n=8,103)
community
(n=120,166)
validated
prediction.
Conclusions:The
stratifies
etiologies
helps
select
at-risk
candidates
surveillance.
Frontiers in Oncology,
Journal Year:
2025,
Volume and Issue:
15
Published: Feb. 20, 2025
This
investigation
aimed
to
create
a
new
nomogram
based
on
complement
C3
forecast
1-,
3-,
and
5-year
overall
survival
(OS)
rates
in
patients
with
early-stage
hepatocellular
carcinoma
(HCC)
exhibiting
microvascular
invasion
(MVI)
post-curative
surgery.
study
encompassed
1234
treated
resection
at
the
Affiliated
Cancer
Hospital
of
Guangxi
Medical
University.
The
cohort
for
primary
included
865
from
December
2015
2019,
while
validation
comprised
369
patients.
Follow-ups
were
conducted
regularly
until
2024.
Variables
predicting
identified
using
Cox
regression
analyses,
these,
was
constructed.
nomogram's
accuracy
assessed
via
time-dependent
ROC
curves,
calibration
curves
KM
curve
analyses.
Investigations
C3,
PT,
presence
cirrhosis,
tumor
capsule,
MVI-M2
as
distinct
predictors
HCC
Based
these
findings,
predictive
constructed
validated,
estimating
OS.
efficacy
validated
through
analyses
each
demonstrating
positive
outcomes.
Additionally,
analysis
effectively
separated
patient
populations
into
two
prognostic
risk
categories
within
both
cohorts.
In
conclusion,
has
been
developed
corroborated
multivariate
analysis,
early
stages
following
surgical
resection.
tool
proven
be
more
effective
forecasting
outcomes
such
World Journal of Gastrointestinal Surgery,
Journal Year:
2025,
Volume and Issue:
17(3)
Published: Feb. 24, 2025
The
high
postoperative
recurrence
rate
remains
a
major
challenge
in
the
treatment
of
hepatocellular
carcinoma
(HCC)
following
resection.
Increasing
research
has
been
delved
into
investigating
role
neoadjuvant
therapy
on
prognosis
resectable
HCC.
Recent
trends
combination
with
molecularly
targeted
agents
and
immune
checkpoint
inhibitors
have
significantly
improved
efficacy
systemic
antitumor
treatments,
yielding
survival
benefits
exceeding
40%.
Neoadjuvant
for
HCC,
whether
based
locoregional
therapies,
or
their
combination,
emerged
as
promising
direction.
However,
there
matter
debate
therapy.
In
this
review,
we
summarize
discuss
progress
challenges
HCC
over
past
five
years
from
perspective
Chinese
guidelines
to
provide
new
insights
future
directions
field.
